INOVIO Pharmaceuticals to present new protein replacement therapeutics research at WODC 2026

INOVIO Pharmaceuticals to present new protein replacement therapeutics research at WODC 2026
INOVIO to present at WODC 2026

INOVIO Pharmaceuticals has announced plans to participate in the World Orphan Drug Congress (WODC) 2026, where it will focus on rare disease protein replacement therapeutics and advancements in next-generation DNA medicine technology.

The company aims to showcase the transformational potential of its research, signaling a continued commitment to innovation in the treatment of rare diseases. Further details about the specific breakthroughs to be presented are anticipated as the event approaches.

INOVIO recently presented new data on its INO-3107 immune therapy showing improved clinical outcomes for recurrent respiratory papillomatosis at ASCO26. Earlier this year, the company shared preclinical results on its DPROT platform aimed at enabling sustained protein production for Hemophilia A at ASGCT2026. These developments reflect INOVIO’s ongoing focus on advanced therapeutics for rare diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.